Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

ClinicalTrials.gov ID: NCT04886596

Public ClinicalTrials.gov record NCT04886596. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above

Study identification

NCT ID
NCT04886596
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
26,675 participants

Conditions and interventions

Interventions

  • Placebo Biological
  • RSVPreF3 OA vaccine Biological

Biological

Eligibility (public fields only)

Age range
60 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 24, 2021
Primary completion
Apr 10, 2022
Completion
May 30, 2024
Last update posted
Jul 30, 2025

2021 – 2024

United States locations

U.S. sites
60
U.S. states
23
U.S. cities
57
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35205
GSK Investigational Site Birmingham Alabama 35211
GSK Investigational Site Huntsville Alabama 35802
GSK Investigational Site Phoenix Arizona 85306
GSK Investigational Site Tucson Arizona 85741
GSK Investigational Site Cerritos California 90703
GSK Investigational Site Laguna Hills California 92653
GSK Investigational Site Coral Gables Florida 33134
GSK Investigational Site Fort Myers Florida 33912
GSK Investigational Site Jacksonville Florida 32205
GSK Investigational Site Lake City Florida 32055
GSK Investigational Site Melbourne Florida 32934
GSK Investigational Site Miami Florida 33174
GSK Investigational Site Orlando Florida 32806
GSK Investigational Site Pinellas Park Florida 33781
GSK Investigational Site The Villages Florida 32162
GSK Investigational Site Weeki Wachee Florida 34607
GSK Investigational Site West Palm Beach Florida 33409
GSK Investigational Site Atlanta Georgia 30328
GSK Investigational Site Chicago Illinois 60602
GSK Investigational Site Evansville Indiana 47714
GSK Investigational Site Mishawaka Indiana 46544
GSK Investigational Site El Dorado Kansas 67042
GSK Investigational Site Newton Kansas 67114
GSK Investigational Site Wichita Kansas 67205
GSK Investigational Site Wichita Kansas 67207
GSK Investigational Site Lexington Kentucky 40509
GSK Investigational Site Rockville Maryland 20854
GSK Investigational Site Richfield Minnesota 55423
GSK Investigational Site Kansas City Missouri 64114
GSK Investigational Site St Louis Missouri 63141
GSK Investigational Site Omaha Nebraska 68134
GSK Investigational Site Henderson Nevada 89052
GSK Investigational Site Binghamton New York 31406
GSK Investigational Site Jamaica New York 10017
GSK Investigational Site Rochester New York 14609
GSK Investigational Site Hickory North Carolina 28601
GSK Investigational Site Rocky Mount North Carolina 27804
GSK Investigational Site Salisbury North Carolina 28144
GSK Investigational Site Statesville North Carolina 28117
GSK Investigational Site Winston-Salem North Carolina 27103
GSK Investigational Site Akron Ohio 44311
GSK Investigational Site Centerville Ohio 45459
GSK Investigational Site Cincinnati Ohio 45236
GSK Investigational Site Columbus Ohio 43212
GSK Investigational Site Erie Pennsylvania 16508
GSK Investigational Site Pittsburgh Pennsylvania 15236
GSK Investigational Site Anderson South Carolina 29621
GSK Investigational Site Mt. Pleasant South Carolina 29405
GSK Investigational Site Knoxville Tennessee 37912
GSK Investigational Site Memphis Tennessee 38119
GSK Investigational Site Dallas Texas 75234
GSK Investigational Site Fort Worth Texas 76104
GSK Investigational Site Houston Texas 77008
GSK Investigational Site Houston Texas 77055
GSK Investigational Site Keller Texas 76248
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Layton Utah 84041
GSK Investigational Site Murray Utah 84106
GSK Investigational Site Norfolk Virginia 23502

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 217 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04886596, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 30, 2025 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04886596 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →